3rdPartyFeeds

Buy Nvidia (NVDA) Stock Ahead of Q1 Earnings, Despite Semiconductor Industry Concerns?

It's time to see if investors should consider buying Nvidia (NVDA) stock before the semiconductor firm reports its Q1 fiscal 2020 financial results on Thursday, May 16. Read More...

Shares of Nvidia NVDA have climbed roughly 30% so far this year as part of the broader market comeback, driven by tech giants such as Apple AAPL and Facebook FB, along with fellow semiconductor firms like Advanced Micro Devices AMD. Despite Nvidia’s overall 2019 strength, NVDA stock has fallen 8% over the last month as reports from some of its peers show continued industry headwinds.

Now, with U.S./China trade war issues back in the headlines again, it’s time to see if investors should consider buying Nvidia stock before it reports its Q1 fiscal 2020 financial results on Thursday, May 16.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Quick Overview ” data-reactid=”13″>Quick Overview

Nvidia had been one of Wall Street’s top performers over the last several years until its October 2018 selloff. The company and many of its peers suffered along with much of the market. However, real issues began to surface in the historically cyclical semiconductor industry. Then, Nvidia, which has long been a GPU giant—helping drive the rise of more life-like graphics in the video game industry—reported poor fiscal fourth-quarter results in early February.

The company’s quarterly revenue dropped 24%, as cryptocurrency-based demand fell. In fact, CEO Jensen Huang said Q4 was “an extraordinary, unusually turbulent, and disappointing quarter.”

Nvidia also faces a potential slowdown in its data center business. On top of all that, we have already seen quarterly results from Intel INTC, AMD, Micron MU, and Lam Research LRCX. Total Q1 earnings for chip companies that have reported results are down -18.5% from the same period last year on -5.5% lower revenues (also read: Detailed Look at Q1 Earnings Season).

As we mentioned at the top, shares of Nvidia have fallen roughly 8% over the last month. Jumping back further, we can see that NVDA has been a top semiconductor performer over a five-year stretch. Shares of Nvidia closed regular trading Wednesday up marginally to $173.92, which marked a roughly 40% downturn compared to its 52-week high.

 

 

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Outlook ” data-reactid=”27″>Outlook

Moving on, our current Zacks Consensus Estimate calls for Nvidia’s Q1 fiscal 2020 revenue to tumble 31.4% to hit $2.20 billion. This would mark an even larger decline than Q4’s 24% fall. Looking ahead to the second quarter, the company’s revenue is projected to slip 17%.

Meanwhile, at the bottom end of the income statement, Nvidia’s adjusted first-quarter earnings are projected to nosedive 60% to $0.82 a share. This negativity is projected to repeat itself to the tune of a 42% earnings decline in the second quarter.

Overall, Nvidia’s adjusted full-year earnings are projected to fall nearly 20% on the back of a 4.5% drop off in sales. Despite the current-year negativity, investors should note that the company’s fiscal 2021 revenues are projected to jump nearly 20% above our 2020 estimate. This would see the company easily top 2019’s $11.72 billion. Furthermore, its 2021 earnings are projected to soar 37% above our current year estimate.

 

 

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Bottom Line” data-reactid=”44″>Bottom Line

Nvidia is currently Zacks Rank #3 (Hold) that has experienced almost zero earnings estimate revision activity over the last 60 days, which means analysts haven’t updated their outlooks. Therefore, it might be best to wait to see Nvidia’s actual quarterly results and how Wall Street reacts. More importantly, those interested in NVDA stock should pay close attention to management’s guidance.

Despite its recent downturn, NVDA stock is trading at 34.4X forward 12-month Zacks Consensus EPS estimates, which marks a significant premium to its industry’s 13.9X average and hovers right around its own five-year median of 32X. Nvidia’s price/sales ratio of 8.9 also rests far above its industry’s 2.48 average. These valuation metrics make Nvidia stock harder to consider at the moment.

In the end though, Nvidia looks set to return to some of the growth that helped its stock price soar for years. The company also announced in early March that it is set to purchase Mellanox MLNX. The deal, which is valued at $6.9 billion, would be Nvidia’s largest-ever purchase. The deal hopes to bolster NVDA’s data center business and more in the cloud computing age.

Nvidia is scheduled to release its Q1 fiscal 2020 earnings results on Thursday, May 16. Make sure to come back to Zacks for a complete breakdown of the firm’s actual quarterly earnings results. 

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now&gt;&gt;” data-reactid=”49″>Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
&nbsp;
Facebook, Inc. (FB) : Free Stock Analysis Report
&nbsp;
Apple Inc. (AAPL) : Free Stock Analysis Report
&nbsp;
Advanced Micro Devices, Inc. (AMD) : Free Stock Analysis Report
&nbsp;
Mellanox Technologies, Ltd. (MLNX) : Free Stock Analysis Report
&nbsp;
NVIDIA Corporation (NVDA) : Free Stock Analysis Report
&nbsp;
Intel Corporation (INTC) : Free Stock Analysis Report
&nbsp;
Micron Technology, Inc. (MU) : Free Stock Analysis Report
&nbsp;
Lam Research Corporation (LRCX) : Free Stock Analysis Report
&nbsp;
To read this article on Zacks.com click here.
&nbsp;
Zacks Investment Research” data-reactid=”50″>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Facebook, Inc. (FB) : Free Stock Analysis Report
 
Apple Inc. (AAPL) : Free Stock Analysis Report
 
Advanced Micro Devices, Inc. (AMD) : Free Stock Analysis Report
 
Mellanox Technologies, Ltd. (MLNX) : Free Stock Analysis Report
 
NVIDIA Corporation (NVDA) : Free Stock Analysis Report
 
Intel Corporation (INTC) : Free Stock Analysis Report
 
Micron Technology, Inc. (MU) : Free Stock Analysis Report
 
Lam Research Corporation (LRCX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Read More

Add Comment

Click here to post a comment